DK2167492T3 - Hidtil ukendt amidderivat til hæmning af væksten af cancerceller - Google Patents

Hidtil ukendt amidderivat til hæmning af væksten af cancerceller Download PDF

Info

Publication number
DK2167492T3
DK2167492T3 DK08766124.5T DK08766124T DK2167492T3 DK 2167492 T3 DK2167492 T3 DK 2167492T3 DK 08766124 T DK08766124 T DK 08766124T DK 2167492 T3 DK2167492 T3 DK 2167492T3
Authority
DK
Denmark
Prior art keywords
yloxy
methoxyquinazolin
chloro
piperidin
prop
Prior art date
Application number
DK08766124.5T
Other languages
English (en)
Inventor
Kwang-Ok Lee
Mi Young Cha
Chang Gon Lee
Se Young Kim
Keukchan Bang
Bum Woo Park
Bo Im Choi
Yun Jung Chae
Young-Gil Ahn
Maeng Sup Kim
Gwan Sun Lee
Mi Ra Kim
Young Hee Jung
Mi Young Ko
Han Kyong Kim
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of DK2167492T3 publication Critical patent/DK2167492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (6)

1. Amidderivat med formlen (I) eller et farmaceutisk acceptabelt salt deraf:
(I) hvori, A er
eller * R4, R5, R6 og R7 hver uafhængigt er hydrogen, halogen, N-Ci_6-alkyl eller /V-hydroxyamido eller C-Ci_6-alkyl-revers amido (-NHCOC1-6), hydroxycarbonyl (-COOH), Ci-6-alkyloxycarbonyl (-COOC1-6), Ci-6-alkyl eller Ci_6-alkyl, som er substitueret med en hydroxygruppe, en Ci-6-dialkylamingruppe eller en heterocyklisk gruppe; Ri er en arylgruppe, som er substitueret med en til fem X, en heterocyklisk gruppe, som er substitueret med en til fem X, eller en Ci-6-alkylgruppe, som er substitueret med aryl; R2 er hydrogen, hydroxy, Ci-6-alkoxy eller Ci-6-alkoxy, som er substitueret med Ci-6-alkoxy eller en heterocyklisk gruppe; R3 er hydrogen, -COOH, Ci.6-alkyloxycarbonyl eller amido, som er /V-usubstitueret eller /V-substitueret med Y; na og nb hver er et heltal i intervallet fra 2 til 6; hvor: X er hydrogen, halogen, hydroxy, cyano, nitro, (mono-, di- eller trihalogen)methyl, mercapto, Ci_6-alkylthio, acrylamido, Ci_6-alkyl, Ci-6-alkenyl, Ci_6-alkynyl, Ci_6-alkoxy, aryloxy, Ci-6-dialkylamino eller Ci-6-alkyl eller Ci-6-alkoxy, som er substitueret med Z, med det forbehold, at når antallet af X er to eller flere, så kan X-grupperne være kondenseret, så de danner en ringstruktur; Y er hydroxy, Ci_6-alkyl eller Ci_6-alkyl, som er substitueret med Z, hvor Ci-6-alkyl indeholder en til fire enheder valgt fra gruppen bestående af N, O, S, SO og S02; og Z er en Ci-6-alkylgruppe, en arylgruppe eller en heterocyklisk gruppe, hvor arylgruppen er en monocyklisk eller bicyklisk, aromatisk C5-i2-gruppe, hvor den heterocykliske gruppe er en monocyklisk eller bicyklisk, aromatisk eller ikke-aromatisk Cs-12-gruppe, som indeholder en til fire enheder valgt fra gruppen bestående af N, O, S, SO og S02, og hvor arylgruppen og den heterocykliske gruppe er usubstituerede eller substitueret med substituenter valgt fra gruppen bestående af halogen, hydroxy, amino, nitro, cyano, Ci-6-alkyl, Ci-6-alkenyl, Ci_6-alkynyl, Ci-6-alkoxy, Ci-6-monoalkylamino og Ci-6-dialkylamino; og hvor udtrykket alkyl henviser til mættede monovalente carbonhydridgrupper med ligekædede, cykliske eller forgrenede enheder.
2. Forbindelse ifølge krav 1, hvor Ri er 3-chlor-4-fluorphenyl, 3- chlor-2-fluorphenyl, 3-chlor-2,4-difluorphenyl, 3,4-dichlor-2-fluorphenyl, 4- brom-3-chlor-2-fluorphenyl, 4-brom-2-fluorphenyl, (R)-1 -phenylethyl, 3- chlor-4-(3-fluorbenzyloxy)phenyl, 3-chlor-4-(pyridin-2-ylmethoxy)phenyl, 1 -(3-fluorbenzyl)-1 H-5-indazol, 3-ethynylphenyl, 4-chlor-2,5-dimethoxyphenyl, 4- brom-3-methylphenyl, 4-isopropylphenyl, 3-methylphenyl, 3-bromphenyl, 3- chlorphenyl, 3,4-dichlorphenyl, 2,3,4-trifluorphenyl, 4-fluor-3-methylphenyl, 3,4-dimethylphenyl, 4-phenyloxyphenyl, 2,3-dihydro-1H-indenyl, 4- hydroxy-3,5-dichlorphenyl, 3-hydroxy-4-chlorphenyl, 4-hydroxy-2-chlorphenyl, 2- hydroxy-4-chlorphenyl, 3-cyanophenyl, 3-trifluormethylphenyl, 3- chlor-2-methoxyphenyl, 4-chlor-3-methylphenyl, 4-brom-3-chlorphenyl, 4- brom-3-fluorphenyl, 3-chlor-2-methylphenyl, 3-dimethylaminophenyl, 2- fluor-3-trifluormethylphenyl, 3-cyano-4-fluorphenyl, 3-cyano-4-chlorphenyl, 3- methylthiophenyl, 2-chlorphenyl, 4-chlorphenyl, 3-chlorphenylmethyl, 3-vinylphenyl, 3-nitrophenyl, 3-acrylamidophenyl, 3-mercaptophenyl, 3- chlormethylphenyl, 4-hydroxy-3-chlorphenyl eller 4-hydroxy-3-fluorphenyl; R2 er hydrogen, hydroxy, methoxy, ethoxy, 3-morpholinopropyloxy eller methoxyethoxy; R3 er hydrogen, methyloxycarbonyl, carboxy, amido, /V-methylamido, /V-ethylamido, /V-propylamido, /V-isopropylamido, /V-hydroxyamido, A/-2-hydroxyethylamido, A/-3-hydroxypropylamido, /V-2-methoxyethylamido, W-2-methylthioethylamido, /V-2-methylsulfonylethylamido, A/-2-A/,A/'-diethylaminoethylamido eller /V-2-morpholinoethylamido; R4, R5, R6 og R7 hver uafhængigt er hydrogen, methyl, 4- methylpiperazinylmethyl, 4-methylpiperazinylethyl, ^/V-dimethylaminomethyl, ^/V-diethylaminomethyl, morpholinomethyl, pyrrolidin-1 -ylmethyl, piperidin-1 -ylmethyl, hydroxymethyl, /V-methylcarboxamido, acetamido, A/-hydroxyamido, methylester, chlor eller carboxy; og na og nb hver uafhængigt er et heltal i intervallet fra 2 til 6.
3. Amidderivat, som er valgt fra gruppen bestående af: 1) 1 -((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 2) (E)-1-((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)but-2-en-1 -on; 3) 1-((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)but-2-yn-1 -on; 4) 1-((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)-5-(4-methylpiperazin-1 -yl)pent-2-yn-1 -on; 5) 1-((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)-4-(dimethylamino)but-2-yn-1 -on; 6) 1-((3S)-3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 7) 1 -((3S)-3-(4-(4-brom-3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 8) 1-((3S)-3-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 9) 1-((3S)-3-(4-(4-brom-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 10) 1 -((3S)-3-(4-(3-chlor-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 11) 1 -((3S)-3-(7-methoxy-4-((1 R)-1 -phenylethylamino)quinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 12) 1 -((3S)-3-(4-(1 -(3-fluorbenzyl)-1 /-/-indazol-5-ylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 13) 1 -((3S)-3-(4-(3-chlor-4-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 14) 1 -((3f?)-3-(4-(3-chlor-4-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 15) 1 -((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)quinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 16) 1 -((3S)-3-(4-(3-chlor-4-(3-fluorbenzyloxy)phenylamino)quinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 17) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 18) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 19) 1 -(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 20) 1-((3f?)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)prop-2-en-1 -on; 21) /V-(2-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)ethyl)acrylamid; 22) 1 -(3-(7-methoxy-4-((1 R)-1 -phenylethylamino)quinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 23) 1-(3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 24) 1-(3-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 25) 1-(3-(4-(3-chlor-4-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 26) 1-(3-(4-(3-chlorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin- 1-yl)prop-2-en-1-on; 27) 3-(6-(1 -acryloylazetidin-3-yloxy)-7-methoxyquinazolin-4-ylamino)benzonitril; 28) (E)-4-(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)-/V-methyl-4-oxobut-2-enamid; 29) 1-(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-methylprop-2-en-1 -on; 30) (Z)-methyl-4-(3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)-4-oxobut-2-enoat; 31) A/-(3-(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-3-oxoprop-1 -en-2-yl)acetamid; 32) (Z)-3-chlor-1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 33) (E)-3-chlor-1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 34) 1-(4-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 35) 1 -(4-(7-methoxy-4-((1 R)-1 -phenylethylamino)quinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 36) 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 37) 1 -(4-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 38) 1-(4-(4-(4-chlor-2,5-dimethoxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 39) 1-(4-(4-(4-brom-3-methylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 40) 1 -(4-(4-(4-isopropylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 41) 1 -(4-(4-(m-toluidino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop- 2-en-1-on; 42) 1-(4-(4-(3-bromphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 43) 1-(4-(4-(3-chlorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 44) 1 -(4-(4-(3,4-dichlorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 45) 1 -(4-(7-methoxy-4-(2,3,4-trifluorphenylamino)quinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 46) 1-(4-(4-(4-fluor-3-methylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 47) 1 -(4-(4-(3,4-dimethylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 48) 1 -(4-(7-methoxy-4-(4-phenoxyphenylamino)quinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 49) 1 -(4-(4-(2,3-d ihydro-1 H-inden-5-ylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 50) 1-(4-(4-(3,5-dichlor-4-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 51) 1 -(4-(4-(4-chlor-3-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 52) 1-(4-(4-(2-chlor-4-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 53) 1-(4-(4-(4-chlor-2-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 54) 1 -(4-(4-(3-chlor-4-(3-fluorbenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 55) 1 -(4-(4-(3-chlor-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 56) 3-(6-(1 -acryloylpiperidin-4-yloxy)-7-methoxyquinazolin-4-ylamino)benzonitril; 57) 1-(4-(4-(3-chlor-4-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 58) 1-(4-(7-methoxy-4-(3-(trifluonriethyl)phenylanriino)quinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 59) 1-(4-(4-(3-chlor-2-methoxyphenylamino)-7-nnethoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 60) 1-(4-(4-(4-chlor-3-methylphenylamino)-7-nnethoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 61) 1 -(4-(4-(4-brom-3-chlorphenylamino)-7-nnethoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 62) 1 -(4-(4-(4-brom-3-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 63) 1-(4-(4-(3-chlor-2-methylphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 64) 1-(4-(4-(3-(dimethylamino)phenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 65) 1-(4-(4-(2-fluor-3-(trifluormethyl)phenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 66) 5-(6-(1 -acryloylpiperidin-4-yloxy)-7-methoxyquinazolin-4-ylamino)-2-fluorbenzonitril; 67) 5-(6-(1 -acryloylpiperidin-4-yloxy)-7-methoxyquinazolin-4-ylamino)-2-chlorbenzonitril; 68) 1 -(4-(7-methoxy-4-(3-(methylthio)phenylamino)quinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 69) 1-(4-(4-(2-chlorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 70) 1-(4-(4-(4-chlorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 71) 1 -(4-(4-(3-chlor-2,4-difluorphenylamino)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 72) 1-(4-(4-(3-chlorbenzylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 73) 1-(4-(7-methoxy-4-(3-vinylphenylamino)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 74) 1-(4-(7-methoxy-4-(3-nitrophenylamino)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 75) A/-(3-(6-(1 -acryloylpiperidin-4-yloxy)-7-quinazolin-4-ylamino)phenyl)acrylamid; 76) 1 -(4-(4-(3-mercaptophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 77) 1 -(4-(4-(3-chlormethyl)phenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 78) 1-(4-(4-(3-chlor-4-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 79) 1-(4-(4-(3-fluor-4-hydroxyphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 80) 1-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)but-2-yn-1 -on; 81) 1 -(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-3-methylbut-2-en-1 -on; 82) (E)-4-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-/V-nnethyl-4-oxobut-2-enannid; 83) (Z)-methyl-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-4-oxobut-2-enoat; 84) (Z)-methyl-(4-(4-(3,4-dichlor-2-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-4-oxobut-2-enoat; 85) (Z)-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-4-oxobut-2-ensyre; 86) (Z)-4-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-4-oxobut-2-ensyre; 87) (E)-4-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-4-oxobut-2-ensyre; 88) (E)-4-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-/V-hydroxy-4-oxobut-2-enannid; 89) (Z)-3-chlor-1 -(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 90) (E)-3-chlor-1 -(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)prop-2-en-1 -on; 91) /V-(3-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-3-oxoprop-1 -en-2-yl)acetamid; 92) (E)-1 -((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)-4-(dimethylannino)but-2-en-1-on; 93) (£)-1 -((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)-4-(dimethylamino)but-2-en-1-on; 94) (£)-1 -((3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)-4-morpholinobut-2-en-1-on; 95) (E)-1 -(3S)-3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)-4-(pyrrolidin-1 -yl)but-2-en-1 -on; 96) (E)-1-((3S)-3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 97) (E)-1-((3S)-3-(4-(3-chlor-2,4-fluorphenylamino)quinazolin-6-yloxy)pyrrolidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 98) (E)-1-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 99) (E)-1-(4-(4-(3,4-dichlor-2-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 100) (E)-1 -(4-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 101) (E)-1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 102) (E)-1 -(3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 103) (E)-/V-(2-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)ethyl)-4-(dimethylamino)but-2-enamid; 104) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-((dimethylamino)methyl)prop-2-en-1 -on; 105) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-((morpholinomethyl)prop-2-en-1 -on; 106) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-((4-methylpiperazin-1 -yl)methyl)prop-2-en-1 -on; 107) 1 -(3-(4-(3-chlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-(piperidin-1 -ylmethyl)prop-2-en-1 -on; 108) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-2-(piperidin-1 -ylmethyl)prop-2-en-1 -on; 109) 1 -(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-2-((dimethylannino)nnethyl)prop-2-en-1-on; 110) 1 -(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-2-(morpholinomethyl)prop-2-en-1 -on; 111) 1-(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-2-((dimethylannino)nnethyl)prop-2-en-1-on; 112) (Z)-1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1 -yl)-4-(dimethylamino)but-2-en-1 -on; 113) (Z)-1 -(4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-2-(dimethylamino)but-2-en-1 -on; 114) 1 -(4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1 -yl)-2-(hydroxymethyl)prop-2-en-1 -on; 115) 1 -(3-(4-(3-chlor-2,4-difluorphenylamino)-7-hydroxyquinazolin-6-yloxy)azetidin-1 -yl)prop-2-en-1 -on; 116) 1-(3-(4-(3-chlor-2,4-difluorphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-on; 117) 1-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 118) 1-(4-(4-(3-chlor-2,4-difluorphenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-on; 119) (2S,4S)-methyl-1-acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxylat; 120) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxannid; 121) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-methylpiperidin-2-carboxannid; 122) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-ethylpiperidin-2-carboxannid; 123) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-propylpiperidin-2-carboxannid; 124) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/\/-isopropylpiperidin-2-carboxannid; 125) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-hydroxypiperidin-2-carboxannid; 126) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-(2-hydroxyethyl)piperidin-2-carboxamid; 127) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-(2-methoxyethyl)piperidin-2-carboxamid; 128) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-(2-(methylthio)ethyl)piperidin-2-carboxamid; 129) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-(2-(methylsulphonyl)ethyl)piperidin-2-carboxamid; 130) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-(2-(dimethylamino)ethyl)pipendin-2-carboxamid; 131) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-(3-hydroxypropyl)piperidin-2-carboxamid; 132) (2S,4S)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-(2-morpholinoethyl)piperidin-2-carboxamid; 133) (2R,4R)-methyl-1 -acryloyl-4-(4-(3-chlor-2,4-d ifluorphenylamino)-7-methoxyquinazolin-6-yloxy)pipendin-2-carboxamid; 134) (2R,4R)-1 -acryloyl-4-(4-(3-chlor-2,4-d ifluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxylsyre; 135) (2R,4R)-1 -acryloyl-4-(4-(3-chlor-2,4-d ifluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxamid; 136) (2R,4R)-1 -acryloyl-4-(4-(3-chlor-2,4-d ifluorphenylamino)-7-methoxyquinazolin-6-yloxy)-A/-methylpiperidin-2-carboxamid; 137) (2R,4R)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-hydroxypiperidin-2-carboxannid; 138) (2R,4R)-1 -acryloyl-4-(4-(3-chlor-2,4-difluorphenylamino)-7-methoxyquinazolin-6-yloxy)-/V-(2-(methylsulphonyl)ethyl)piperidin-2-carboxamid; 139) (2R,4R)-1 -acryloyl-4-(4-(3,4-dichlor-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxamid og 140) (2R,4R)-1 -acryloyl-4-(4-(4-brom-2-fluorphenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxannid.
4. Farmaceutisk sammensætning til anvendelse til hæmning afvæksten af cancerceller, hvilken sammensætning omfatter amidderivatet eller dets farmaceutisk acceptable salt ifølge krav 1 eller 3 som aktiv bestanddel.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 4, som administreres i kombination med et andet middel mod cancer valgt fra gruppen bestående af cellesignaltransduktionshæmmere, mitosehæmmere, alkyleringsmidler, antimetabolitter, antibiotika, vækstfaktorhæmmere, cellecyklushæmmere, topoisomerasehæmmere, modifikatorer af biologiske reaktioner, antihormonelle midler og antiandrogen.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor væksten af cancerceller er induceret af overekspression af EGFR, Erb-B2 eller mutation af EGFR.
DK08766124.5T 2007-06-05 2008-06-05 Hidtil ukendt amidderivat til hæmning af væksten af cancerceller DK2167492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070054997 2007-06-05
PCT/KR2008/003162 WO2008150118A2 (en) 2007-06-05 2008-06-05 Novel amide derivative for inhibiting the growth of cancer cells

Publications (1)

Publication Number Publication Date
DK2167492T3 true DK2167492T3 (da) 2016-01-11

Family

ID=40094307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08766124.5T DK2167492T3 (da) 2007-06-05 2008-06-05 Hidtil ukendt amidderivat til hæmning af væksten af cancerceller

Country Status (25)

Country Link
US (1) US8188102B2 (da)
EP (1) EP2167492B1 (da)
JP (1) JP5155391B2 (da)
KR (1) KR101013319B1 (da)
CN (1) CN101679384B (da)
AR (2) AR066876A1 (da)
AU (1) AU2008260772B2 (da)
BR (1) BRPI0811069B1 (da)
CA (1) CA2687180C (da)
DK (1) DK2167492T3 (da)
ES (1) ES2558623T3 (da)
HK (1) HK1142591A1 (da)
HR (1) HRP20160007T1 (da)
HU (1) HUE028243T2 (da)
IL (1) IL202154A (da)
MX (1) MX2009012772A (da)
MY (1) MY144972A (da)
NZ (1) NZ582412A (da)
PL (1) PL2167492T3 (da)
PT (1) PT2167492E (da)
RU (1) RU2434010C2 (da)
TW (1) TWI377944B (da)
UA (1) UA96045C2 (da)
WO (1) WO2008150118A2 (da)
ZA (1) ZA201000022B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JP6353788B2 (ja) 2012-01-13 2018-07-04 エイシア バイオサイエンシーズ インコーポレイテッド 抗がん剤としての複素環式化合物およびその使用
EP2805940B1 (en) 2012-01-17 2016-11-23 Astellas Pharma Inc. Pyrazine carboxamide compound
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
RU2677653C2 (ru) 2013-07-11 2019-01-18 Ацея Байосайенсиз Инк. Производные пиримидина в качестве ингибиторов киназы
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
WO2016150340A1 (zh) * 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN113149960A (zh) * 2016-08-25 2021-07-23 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐的晶体
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
WO2018115380A1 (en) * 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3590929B1 (en) 2017-02-28 2021-09-15 Medshine Discovery Inc. Spiro compound and use thereof
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
WO2019120213A1 (zh) 2017-12-19 2019-06-27 南京明德新药研发股份有限公司 喹唑啉衍生物及其应用
CR20210307A (es) 2017-12-21 2021-07-27 Boehringer Ingelheim Int NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)
KR20200136417A (ko) * 2018-03-27 2020-12-07 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Her2 엑손 19 돌연변이를 보유하는 암 세포에 대해 항 종양 활성을 갖는 화합물
CN110054613B (zh) * 2018-05-24 2020-11-27 深圳市塔吉瑞生物医药有限公司 取代的氨基喹唑啉类化合物及其药物组合物及其用途
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN108623490A (zh) * 2018-06-22 2018-10-09 苏州市贝克生物科技有限公司 (2z)-4-(二甲基氨基)-2-丁烯酸盐酸盐的合成方法
WO2020005932A1 (en) 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
CN112823153A (zh) * 2018-09-14 2021-05-18 韩美制药有限公司 喹唑啉化合物及其盐酸盐的结晶形式
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CA3113241A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
KR101950942B1 (ko) 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
IL299831A (en) 2019-03-19 2023-03-01 Voronoi Inc The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
EP3962908A4 (en) 2019-04-25 2022-10-26 Board of Regents, The University of Texas System HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
CA3138348A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
EP3988553A4 (en) * 2019-06-19 2023-06-14 Chengdu Jinrui Foundation Biotech Co., Ltd. CRYSTALLINE AND SALT FORM OF A QUINAZOLINE COMPOUND, AND METHOD FOR THE PREPARATION THEREOF
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
KR20210049004A (ko) 2019-10-24 2021-05-04 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
US20230121116A1 (en) * 2020-01-29 2023-04-20 Board Of Regents, The University Of Texas System Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN111763215B (zh) * 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN115803326B (zh) * 2020-11-23 2024-03-26 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2022170043A1 (en) * 2021-02-05 2022-08-11 Accutar Biotechnology, Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
JP2024523861A (ja) 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
WO2022266427A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
KR20240069728A (ko) * 2021-08-24 2024-05-20 아쓰로시 테라퓨틱스, 인크. 질환의 치료를 위한 퀴나졸린 화합물
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用
WO2023128350A1 (ko) * 2021-12-30 2023-07-06 주식회사 비투에스바이오 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
MXPA04009536A (es) * 2002-03-30 2005-01-25 Boehringer Ingelheim Pharma Compuestos heterociclos biciclicos, composiciones farmaceuticas que contienen estos compuestos, su utilizacion y procesos para su preparacion.
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
AU2004261477A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
CA2539022A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
JP2007506716A (ja) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
CN1934100A (zh) 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
WO2007023073A2 (de) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2007055513A1 (en) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof

Also Published As

Publication number Publication date
KR20080107294A (ko) 2008-12-10
TWI377944B (en) 2012-12-01
CN101679384B (zh) 2013-10-16
KR101013319B1 (ko) 2011-02-09
RU2009149307A (ru) 2011-07-20
JP5155391B2 (ja) 2013-03-06
ES2558623T3 (es) 2016-02-05
HRP20160007T1 (hr) 2016-02-12
IL202154A (en) 2014-05-28
PT2167492E (pt) 2016-02-04
PL2167492T3 (pl) 2016-03-31
JP2010529115A (ja) 2010-08-26
EP2167492A4 (en) 2010-12-15
US20100179120A1 (en) 2010-07-15
CA2687180C (en) 2012-07-24
MX2009012772A (es) 2009-12-15
AR066876A1 (es) 2009-09-16
WO2008150118A3 (en) 2009-01-29
TW200906414A (en) 2009-02-16
US8188102B2 (en) 2012-05-29
HUE028243T2 (en) 2016-12-28
HK1142591A1 (en) 2010-12-10
BRPI0811069A2 (pt) 2014-12-09
AU2008260772A1 (en) 2008-12-11
MY144972A (en) 2011-11-30
AU2008260772B2 (en) 2011-06-02
CN101679384A (zh) 2010-03-24
BRPI0811069B1 (pt) 2022-08-30
AR110003A2 (es) 2019-02-13
WO2008150118A2 (en) 2008-12-11
ZA201000022B (en) 2011-04-28
UA96045C2 (ru) 2011-09-26
EP2167492A2 (en) 2010-03-31
EP2167492B1 (en) 2015-10-14
IL202154A0 (en) 2010-06-16
CA2687180A1 (en) 2008-12-11
NZ582412A (en) 2011-12-22
RU2434010C2 (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
DK2167492T3 (da) Hidtil ukendt amidderivat til hæmning af væksten af cancerceller
JP6945015B2 (ja) Ｎ２，ｎ４−ジフェニルピリミジン−２，４−ジアミン誘導体、その製造方法、およびこれを有効成分として含む癌の予防または治療用の薬学的組成物
WO2011093672A2 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
IL286471B2 (en) The history of phenylisoxazolidine (pyridine-amino-phenyl)-acrylamide, a method for their preparation and a pharmaceutical preparation containing them
WO2012027960A1 (zh) 苯胺取代的喹唑啉衍生物及其制备方法与应用
WO2006071079A1 (en) Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
CN111732548A (zh) N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
US20230106731A1 (en) Inhibitors of mutant family tyrosine-kinases
CA3211588A1 (en) Novel pyrimidine derivative showing inhibition effect on growth of cancer cells
RU2789405C2 (ru) Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение
CN118772111A (zh) 一种取代的氨基嘧啶类化合物、药物组合物及其用途
EA041822B1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
AU2010319382A1 (en) Kinase inhibitors